• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

BTK inhibitors

BeOne
Pharma

BeOne’s Brukinsa hits goal in lymphoma confirmatory trial

Overall survival data will likely be key in BeOne’s approval bid, given Imbruvica’s earlier U.S. withdrawal in MCL.
Angus Liu Jun 30, 2026 6:00am
VanNaarden

Lilly oncology chief ‘blown away’ by new Jaypirca CLL data

Jun 15, 2026 8:25am
Jaypirca

Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial

Apr 13, 2026 10:16am
FDA approved stamp regulations yes go

AZ nabs Calquence fixed-duration nod to counter BeOne’s CLL push

Feb 20, 2026 11:05am
NVS

Novartis jockeys for Rhapsido FDA nod in unclaimed hives subtype

Feb 18, 2026 9:49am
Narasimhan

Novartis CEO eyes 2026 growth despite record patent cliff

Feb 4, 2026 2:30pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings